Palo Alto Investors »

Taysha Gene Therapies shares owned by Palo Alto Investors

Quarter-by-quarter ownership of Taysha Gene Therapies (TSHA) shares owned by Palo Alto Investors from 13F filings

Historical chart of Palo Alto Investors investment in Taysha Gene Therapies

Tip: Access up to 7 years of quarterly data

All positions including Taysha Gene Therapies held by Palo Alto Investors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Taysha Gene Therapies by Palo Alto Investors

Quarter filed Position value Share count Share price at filing
2023-12-31 $938k 530k 1.77

More positions owned by Palo Alto Investors

Insmed Com Par $.01 (INSM)
Amicus Therapeutics (FOLD)
BioMarin Pharmaceutical (BMRN)
Biogen Idec (BIIB)
United Therapeutics Corporation (UTHR)
ACADIA Pharmaceuticals (ACAD)
Prothena Corp SHS (PRTA)
Revance Therapeutics (RVNC)
Staar Surgical Com Par $0.01 (STAA)
Alnylam Pharmaceuticals (ALNY)
eHealth (EHTH)
Sage Therapeutics (SAGE)
Sarepta Therapeutics (SRPT)
Iovance Biotherapeutics (IOVA)
Alkermes SHS (ALKS)

View all positions for Palo Alto Investors

Top funds holding Taysha Gene Therapies

RA Capital Management
VR Adviser
Vanguard Group
venBio Select Advisor
Baker Bros. Advisors
Artal Group
Millennium Management
Point72 Asset Management
Citadel Advisors
T. Rowe Price Associates
Schonfeld Strategic Advisors
Exome Asset Management
Alphabet
Quantum Private Wealth
Palo Alto Investors

View all funds holding Taysha Gene Therapies